



## Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

November 09, 2023

On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023.

ALK will host a meeting for analysts and institutional investors that day at 1.30pm (CET) at which Management will review the financial results, the outlook and answer questions.

The meeting will be audio cast live on our website <https://ir.alk.net>, where the related presentation will be available shortly before the meeting begins.

To register for the conference call, please use this link <https://dpreregister.com/sreg/10183783/fad25cbd21> and follow the instructions. You will receive an email from [diamondpass@choruscall.com](mailto:diamondpass@choruscall.com) with dial-in details, including a passcode and a pin code. Please make sure to whitelist [diamondpass@choruscall.com](mailto:diamondpass@choruscall.com) and/or check your spam filter. We advise you to register on the day before the call at the latest.

### ALK-Abelló A/S

#### For further information please contact:

*Investor Relations:* Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

*Media:* Maiken Riise Andersen, tel. +45 5054 1434

#### **About ALK**

*ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at [www.alk.net](http://www.alk.net).*

#### Attachment

- [InvestorNews\\_09Nov23](#)